Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Normal-Weight diabetes: can fat cell therapy work?

NCT ID NCT06657209

First seen May 17, 2026 · Last updated May 25, 2026 · Updated 2 times

Summary

This study looks at how fat cells work in people with normal-weight type 2 diabetes compared to those with overweight diabetes or no diabetes. Researchers will test two drugs, pioglitazone and tirzepatide, to see if they improve insulin resistance and fat storage. About 104 adults aged 30-70 with normal weight and type 2 diabetes or prediabetes will participate. The goal is to find better treatments for this often-overlooked group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Stanford University, Clinical and Translational Research Unit (CTRU)

    NOT_YET_RECRUITING

    Stanford, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.